VivoSeq
Other

Gastric

1

Pipeline Programs↗

6

Active Trials↗

16

Companies Involved↗

Gastric is an early-stage landscape with 1 program across 16 companies. The most active players are Astellas, Trio Medicines Ltd., AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

1 program

PreclinicalT

Trio Medicines Ltd.

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

ASP546C

Astellas

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

73

clinical trials

Completed53 · 73%
Terminated7 · 10%
Unknown status6 · 8%
Recruiting4 · 5%
Not yet recruiting2 · 3%
Suspended1 · 1%

Clinical Trials

Trial Activity

73 trials

Time-dependent Association Between Cessation of Glucagon-like Peptide-1 Receptor Agonists and Residual Gastric Contents Assessed by Point-of-care Gastric Ultrasound: a Prospective Observational Study
Recruiting·WWonkwang University Hospital·N/A·NCT07623148·186 enrolled
GI Windows Flexagon Self Forming Magnet Anastomosis Plus OTOLoc for Creating Gastric-Jejunal Anastomoses in Patients Undergoing Surgical Procedures
Recruiting·GGI Windows, Inc.·Preclinical·NCT06915337·75 enrolled
A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types
Recruiting·Astellas logoAstellas·Preclinical·NCT07488676·150 enrolled
Evaluation of Post-Omega Bypass Excluded Stomach Fundoplication to Treat Disabling Gastroesophageal Reflux Disease Resistant to Medical Treatment and Requiring Surgery
Recruiting·GGCS Ramsay Santé pour l'Enseignement et la Recherche·Preclinical·NCT06621979·17 enrolled
Effect of Miralax NPO Time on Residual Gastric Volumes and Bowel Preparation
Not yet recruiting·SStanford University·Preclinical·NCT07616908·200 enrolled
Efficacy of an Anti-Bloating Patch for Postoperative Gastric Distension After Cardiac Surgery: A Randomized Controlled Trial Using Quantitative Gastric Bubble Imaging Analysis
Not yet recruiting·SSoutheast University, China·Preclinical·NCT07677423·150 enrolled
Nordic Gastric and Esophageal Tumor Study
Completed·KKarolinska Institutet·N/A·NCT05688761·900,000 enrolled
Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT01694706·15 enrolled
Effect of Vecam 40/300 and Vecam 20/300 Compared to Omeprazole 20 mg on Gastric pH
Completed·VVecta Ltd.·Phase 1·NCT00818870·60 enrolled
Gastric Volumes by US in Term Parturients Undergoing CS With and Without Metoclopramide
Completed·NNorthwestern University·Phase 4·NCT05033041·72 enrolled
Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass
Completed·RRijnstate Hospital·Phase 4·NCT02271997·120 enrolled
Evaluation of Rebamipide and Rabeprazole Effect Associated or Not to Prevent Naproxen-induced Gastric Lesions
Completed·GGaleno Desenvolvimento de Pesquisas Clínicas·Phase 3·NCT03658473·32 enrolled
Phenotypical Approach of the Drug Metabolizing Hormones Activity Before and After Roux-en Y-Gastric Bypass
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1·NCT01443039·11 enrolled
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
Completed·AstraZeneca logoAstraZeneca·Phase 4·NCT00206050·40 enrolled
Intragastric pH and Bismuth Effect for H. Pylori Eradication
Completed·NNational Taiwan University Hospital·N/A·NCT02894892·21 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)